Foghorn therapeutics provides second quarter 2024 financial and corporate update

Topline phase 1 dose escalation data for fhd-286 in combination with decitabine, in relapsed and/or refractory aml patients, anticipated in the fourth quarter of 2024

FHTX Ratings Summary

FHTX Quant Ranking